Home >> Healthcare Administration >> Pharmaceuticals >> Food & Beverage >>

Pulmonary Fibrosis - Pipeline Review, H2 2013

Published: Nov-2013 | Format: PDF | Global Markets Direct | Number of pages: 92 | Code: MRS - 982

Global Markets Directs, 'Pulmonary Fibrosis Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Scope

A snapshot of the global therapeutic scenario for Pulmonary Fibrosis.
A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy


Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pulmonary Fibrosis Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Pulmonary Fibrosis 9
Pulmonary Fibrosis Therapeutics under Development by Companies 11
Pulmonary Fibrosis Therapeutics under Investigation by Universities/Institutes 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Pulmonary Fibrosis Therapeutics - Products under Development by Companies 16
Pulmonary Fibrosis Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Pulmonary Fibrosis Therapeutics Development 18
Eli Lilly and Company 18
Lpath, Inc. 19
Mesoblast Ltd 20
NicOx SA 21
Oncothyreon Inc 22
Pharmaxis Ltd. 23
Paloma Pharmaceuticals, Inc. 24
Digna Biotech, S.L. 25
Aquinox Pharmaceuticals Inc. 26
Angion Biomedica Corp. 27
Centocor Ortho Biotech, Inc. 28
Fibrotech Therapeutics Pty. Ltd. 29
FCB-Pharmicell Co.,Ltd. 30
Clarassance, Inc. 31
Pulmonary Fibrosis - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
Lpathomab - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
P-17 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AZX-100 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
PX-866 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
STNM-04 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
P-529 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AQX-1125 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Btx-201 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
GR-MD-02 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Drug For Osteoarthritis and Pulmonary Fibrosis - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ICG-001 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CG-1011 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ANG-3298 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
C-201 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Galectin-3 Inhibitors - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
SDP-051 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
FT-011 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CT-140 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PDE-4A4 Inhibitors - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
NCX-466 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MC-1575 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Lungcellgram - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CpG Oligonucleotides - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Allogeneic Mesenchymal Precursor Cells For Asthma And Pulmonary Fibrosis - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
LY-2109761 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PXS-5033-A - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Transforming Growth Factor Beta Receptor Antagonists - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Drug Inhibiting IGF-1R - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Pulmonary Fibrosis Therapeutics - Drug Profile Updates 72
Pulmonary Fibrosis Therapeutics - Discontinued Products 84
Pulmonary Fibrosis Therapeutics - Dormant Products 85
Pulmonary Fibrosis - Product Development Milestones 86
Featured News & Press Releases 86
Jul 11, 2013: ProMetic's Lead Drug Candidate, PBI-4050, on Track to Enter Clinical Trial Program in September 2013 86
Jun 05, 2013: Genoa Pharma And McMaster University Demonstrate In Vivo Benefit Of Inhaled Pirfenidone Offering Greater Pulmonary Fibrosis Efficacy Than Oral Therapy 86
May 08, 2012: Boehringer Ingelheim To Present Additional Data From Phase II Study Of BIBF 1120 At ATS 2012 87
Jul 06, 2011: Capstone Reports Positive Pre-Clinical Results Of AZX100 In Pulmonary Fibrosis 87
Mar 05, 2010: ImmuneRegen Forms Partnership With Bachem For Manufacturing Of Homspera 88
May 18, 2009: Oncothyreon's PX-866 Is Effective In Preclinical Model Of Pulmonary Fibrosis 89
Mar 17, 2009: Compugen Announces Positive Therapeutic Effects Of Relaxin Receptor Peptide Ligand CGEN-25009 In Pulmonary Fibrosis Animal Model 89

Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 92
Disclaimer 92


List of Tables

Number of Products Under Development for Pulmonary Fibrosis, H2 2013 9
Products under Development for Pulmonary Fibrosis - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Early Clinical Stage Development, H2 2013 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
Eli Lilly and Company, H2 2013 18
Lpath, Inc., H2 2013 19
Mesoblast Ltd, H2 2013 20
NicOx SA, H2 2013 21
Oncothyreon Inc, H2 2013 22
Pharmaxis Ltd., H2 2013 23
Paloma Pharmaceuticals, Inc., H2 2013 24
Digna Biotech, S.L., H2 2013 25
Aquinox Pharmaceuticals Inc., H2 2013 26
Angion Biomedica Corp., H2 2013 27
Centocor Ortho Biotech, Inc., H2 2013 28
Fibrotech Therapeutics Pty. Ltd., H2 2013 29
FCB-Pharmicell Co.,Ltd., H2 2013 30
Clarassance, Inc., H2 2013 31
Assessment by Monotherapy Products, H2 2013 32
Assessment by Stage and Route of Administration, H2 2013 34
Assessment by Stage and Molecule Type, H2 2013 36
Pulmonary Fibrosis Therapeutics - Drug Profile Updates 72
Pulmonary Fibrosis Therapeutics - Discontinued Products 84
Pulmonary Fibrosis Therapeutics - Dormant Products 85 
List of Figures

Number of Products under Development for Pulmonary Fibrosis, H2 2013 9
Products under Development for Pulmonary Fibrosis - Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 13
Early Clinical Stage Products, H2 2013 14
Discovery and Pre-Clinical Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 32
Assessment by Route of Administration, H2 2013 33
Assessment by Stage and Route of Administration, H2 2013 34
Assessment by Molecule Type, H2 2013 35
Assessment by Stage and Molecule Type, H2 2013 36

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing